Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders

Annual Review of Neuroscience

Volumn 26, Issue , 2003, Pages 267-298

  Caughey, Byron ^a   Lansbury Jr , Peter T ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alzheimer's; Amyloid; Parkinson's; Prion; Scrapie

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN SPONGIOSIS; CELL CULTURE; CELL DEATH; CELL KILLING; CONTROLLED STUDY; DEGENERATIVE DISEASE; GENETICS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW;

AMYLOID BETA-PROTEIN; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; PRIONS; PRPSC PROTEINS; SENILE PLAQUES; SUPEROXIDE DISMUTASE; SYNUCLEINS;

EID: 0037551741     PISSN: 0147006X     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.neuro.26.010302.081142     Document Type: Review

References (199)

1. Al-Chalabi A, Leigh PN. 2000. Recent advances in amyotrophic lateral sclerosis. Curr. Opin. Neurol. 13:397-405
2. Andersen PM, Nilsson P, Ala-Hurula V, Keranen ML, Tarvainen I, et al. 1995. Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Nat. Genet. 10:61-66
3. Andersen PM, Nilsson P, Keranen ML, Forsgren L, Hagglund J, et al. 1997. Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. Brain 120:1723-37
4. Arispe N, Pollard HB, Rojas E. 1993. Giant multilevel cation channels formed by Alzheimer's disease amyloid β-protein [AβP(1-40] in bilayer membranes. Proc. Nat. Acad. Sci. USA 90:10,573-77
5. Arispe N, Doh M. 2002. Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AbetaP (1-40) and (1-42) peptides. FASEB J. 16:1526-36
6. Arispe N, Pollard HB, Rojas E. 1996. Zn2+ interaction with Alzheimer amyloid beta protein calcium channels. Proc. Natl. Acad. Sci. USA 93:1710-15
7. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. 2002. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295:865-68
8. Baldwin MA. 2001. Mass spectrometric analysis of prion proteins. Adv. Protein Chem. 57:29-54
9. Baron GS, Wehrly K, Dorward DW, Chesebro B, Caughey B. 2002. Conversion of raft associated prion protein to the protease-resistant state requires insertion of PrPres (PrP(Sc)) into contiguous membranes. EMBO J. 21(5):1031-40
10. Baskakov IV, Legname G, Baldwin MA, Prusiner SB, Cohen FE. 2002. Pathway complexity of prion protein assembly into amyloid. J. Biol. Chem. 277(24):21,140-48
11. Bence NF, Sampat RM, Kopito RR. 2001. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292:1552-55
12. Benveniste H, Einstein G, Kim KR, Hulette C, Johnson GA. 1999. Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc. Natl. Acad. Sci. USA 96:14,079-84
13. Bessen RA, Raymond GJ, Caughey B. 1997. In situ formation of protease-resistant prion protein in transmissible spongiform encephalopathy-infected brain slices. J. Biol. Chem. 272:15,227-31
14. Borchelt DR, Taraboulos A, Prusiner SB. 1992. Evidence for synthesis of scrapie prion protein in the endocytic pathway. J. Biol. Chem. 267:16,188-99
15. Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, et al. 1996. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379:339-43
16. Brown P, Liberski P, Wolff A, Gajdusek DC. 1990. Conservation of infectivity in purified fibrillary extracts of scrapie-infected hamster brain after sequential enzymatic digestion or polyacrylamide gel electrophoresis. Proc. Natl. Acad. Sci. USA 87:7240-44
17. Brown RH Jr. 1997. Amyotrophic lateral sclerosis. Insights from genetics. Arch. Neurol. 54:1246-50
18. Bruce ME, McBride PA, Farquhar CF. 1989. Precise targeting of the pathology of the sialoglycoprotein, PrP, and vacuolar degeneration in mouse scrapie. Neurosci. Lett. 102:1-6
19. Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, et al. 1998. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281:1851-54
20. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, et al. 2002. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416:507-11
21. Bueler H, Aguzzi A, Sailer A, Greiner R-A, Autenried P, et al. 1993. Mice devoid of PrP are resistant to scrapie. Cell 73:1339-47
22. Callahan MA, Xiong L, Caughey B. 2001. Reversibility of scrapie-associated prion protein aggregation. J. Biol. Chem. 276(30):28,022-28
23. Caughey B. 1991. Cellular metabolism of normal and scrapie-associated forms of PrP. Sem. Virol. 2:189-96
24. Caughey B. 2001. Interactions between prion protein isoforms: the kiss of death? Trends Biochem. Sci. 26(4):235-42
25. Caughey B, Raymond GJ. 1991. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J. Biol. Chem. 266:18,217-23
26. Caughey B, Raymond GJ, Callahan MA, Wong C, Baron GS, Xiong L. 2001. Interactions and conversions of prion protein isoforms. Adv. Prot. Chem. 57:139-69
27. Caughey B, Raymond GJ, Ernst D, Race RE. 1991. N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state. J. Virol. 65:6597-603
28. Chiesa R, Drisaldi B, Quaglio E, Migheli A, Piccardo P, et al. 2000. Accumulation of protease-resistant prion protein (PrP) and apoptosis of cerebellar granule cells in transgenic mice expressing a PrP insertional mutation. Proc. Natl. Acad. Sci. USA 97(10):5574-79
29. Clarke G, Collins RA, Leavitt BR, Andrews DF, Hayden MR, et al. 2000. A one-hit model of cell death in inherited neuronal degenerations. Nature 406:195-99
30. Cleveland DW. 1999. From Charcot to SOD1: mechanisms of selective motor neuron death in ALS. Neuron 24:515-20
31. Cleveland DW, Liu J. 2000. Oxidation versus aggregation - How do SOD1 mutants cause ALS? Nat. Med. 6:1320-21
32. Conway KA, Harper JD, Lansbury PT. 1998. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4:1318-20
33. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr. 2000. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97:571-76
34. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. 2001. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294:1346-49
35. Cordeiro Y, Machado F, Juliano L, Juliano MA, Brentani RR, et al. 2001. DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation. J. Biol. Chem. 276(52):49,400-9
36. Crook R, Verkkoniemi A, Perez-Tur J, Mehta N, Baker M, et al. 1998. A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat. Med. 4:452-55
37. Dahlgren KA, Manelli AM, Stine WB, Baker LK, Krafft GA, LaDu MJ. 2002. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol. Chem. 277:32,046-53
38. Dauer W, Kholodolvov N, Vila M, Trillat AC, Goodhild R, et al. 2002. Resistance of α-synucelin null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. USA 99:14,524-29
39. DeArmond SJ, Qiu Y, Sanchez H, Spilman PR, Ninchak-Casey A, et al. 1999. PrPC glycoform heterogeneity as a function of brain region: implications for selective targeting of neurons by prion strains. J. Neuropathol. Exp. Neurol. 58(9):1000-9
40. DeArmond SJ, Yang SL, Lee A, Bowler R, Taraboulos A, et al. 1993. Three scrapie prion isolates exhibit different accumulation patterns of the prion protein scrapie isoform. Proc. Natl. Acad. Sci. USA 90(14):6449-53
41. Ding TT, Lee SJ, Rochet JC, Lansbury PT Jr. 2002. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 41:10,209-17
42. Diringer H, Gelderblom H, Hilmert H, Ozel M, Edelbluth C, Kimberlin RH. 1983. Scrapie infectivity, fibrils and low molecular weight protein. Nature 306:476-78
43. Dobson CM. 1999. Protein misfolding, evolution and disease. Trends Biochem. Sci. 24:329-32
44. Duff K, Eckman C, Zehr C, Yu X, Prada CM, et al. 1996. Nature 383(6602):710-13
45. Durham HD, Roy J, Dong L, Figlewicz DA. 1997. Aggregation of mutant Cu/ Zn superoxide dismutase proteins in a culture model of ALS. J. Neuropathol. Exp. Neurol. 56:523-30
46. Eigen M. 1996. Prionics or the kinetic basis of prion diseases. Biophys. Chem. 63:A1-18
47. El-Agnaf OM, Nagala S, Patel BP, Austen BM. 2001a. Non-fibrillar oligomeric species of the amyloid ABri peptide, implicated in familial British dementia, are more potent in inducing apoptotic cell death than protofibrils or fibrils. J. Mol. Biol. 310:157-68
48. Feany MB, Bender WW. 2000. A Drosophila model of Parkinson's disease. Nature 404:394-98
49. Fezoui Y, Hartley DM, Walsh DM, Selkoe DJ, Osterhout JJ, et al. 2000. A de novo designed helix-turn-helix peptide forms amyloid fibrils. Nat. Struct. Biol. 7(12):1095-99
50. Gabizon R, McKinley MP, Groth DF, Kenaga L, Prusiner SB. 1988. Properties of scrapie prion protein liposomes. J. Biol. Chem. 263:4950-55
51. George JM, Jin H, Woods WS, Clayton DF. 1995. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15:361-72
52. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. 2002. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34:521-33
53. Giese A, Brown DR, Groschup MH, Feldmann C, Haist I, Kretzschmar HA. 1998. Role of microglia in neuronal cell death in prion disease. Brain Pathol. 8(3):449-57
54. Glockshuber R. 2001. Folding dynamics and energetics of recombinant prion proteins. Adv. Prot. Chem. 57:83-105
55. Goldberg MS, Lansbury PT Jr. 2000. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol. 2:E115-19
56. Gosavi N, Lee HJ, Lee JS, Patel S, Lee SJ. 2002. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 277:48,984-92
57. Gu Y, Fujioka H, Mishra RS, Li R, Singh N. 2002. Prion peptide 106-126 modulates the aggregation of cellular prion protein and induces the synthesis of potentially neurotoxic transmembrane PrP. J. Biol. Chem. 277(3):2275-86
58. Haass C, Steiner H. 2001. Protofibrils, the unifying toxic molecule of neurodegenerative disorders? Nat. Neurosci. 4:859-60
59. Hand CK, Mayeux-Portas V, Khoris J, Briolotti V, Clavelou P, et al. 2001. Compound heterozygous D90A and D96N SOD1 mutations in a recessive amyotrophic lateral sclerosis family. Ann. Neurol. 49:267-71
60. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-56
61. Harper JD, Lansbury PT Jr. 1997. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66:385-407
62. Harper JD, Lieber CM, Lansbury PT Jr. 1997a. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. Chem. Biol. 4:951-59
63. Harper JD, Wong SS, Lieber CM, Lansbury PT. 1997b. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem. Biol. 4:119-25
64. Harper JD, Wong SS, Lieber CM, Lansbury PT Jr. 1999. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry 38:8972-80
65. Harris DA. 2001. Biosynthesis and cellular processing of the prion protein. Adv. Prot. Chem. 57:203-28
66. Hartl FU, Hayer-Hartl M. 2002. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295:1852-58
67. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, et al. 1999. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in conical neurons. J. Neurosci. 19:8876-84
68. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E. 2001. Beta-synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32:213-23
69. Hayward C, Brock DJ, Minns RA, Swingler RJ. 1998. Homozygosity for Asn86Ser mutation in the CuZn-superoxide dismutase gene produces a severe clinical phenotype in a juvenile onset case of familial amyotrophic lateral sclerosis. J. Med. Genet. 35:174
70. Hayward LJ, Rodriguez JA, Kim JW, Tiwari A, Goto JJ, et al. 2002. Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial amyotrophic lateral sclerosis. J. Biol. Chem. 277:15,923-31
71. Hegde RS, Tremblay P, Groth D, DeArmond SJ, Prusiner SB, Lingappa VR. 1999. Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 402(6763):822-26
72. Herrmann LM, Caughey B. 1998. The importance of the disulfide bond in prion protein conversion. Neuroreport 9:2457-61
73. Hill AF, Antoniou M, Collinge J. 1999. Protease-resistant prion protein produced in vitro lacks detectable infectivity. J. Gen. Virol. 80(Pt. 1):11-14
74. Hirano A, Nakano I, Kurland LT, Mulder DW, Holley PW, Saccomanno G. 1984. Fine structural study of neurofibfillary changes in a family with amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 43:471-80
75. Hope J. 1994. The nature of the scrapie agent: the evolution of the virino. Ann. NY Acad. Sci. 724:282-89
76. Hope J, Morton LJD, Farquhar CF, Multhaup G, Beyreuther K, Kimberlin RH. 1986. The major polypeptide of scrapie-associated fibrils (SAF) has the same size, charge distribution and N-terminal protein sequence as predicted for the normal brain protein (PrP). EMBO J. 5:2591-97
77. Hope J, Multhaup G, Reekie LJD, Kimberlin RH, Beyreuther K. 1988. Molecular pathology of scrapie-associated fibril protein (PrP) in mouse brain affected by the ME7 strain of scrapie. Eur. J. Biochem. 172:271-77
78. Horiuchi M, Chabry J, Caughey B. 1999. Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J. 18(12):3193-203
79. Houlden H, Baker M, McGowan E, Lewis P, Hutton M, et al. 2000. Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-beta concentrations. Ann. Neurol. 48:806-8
80. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, et al. 1999. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA 96:3228-33
81. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, et al. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274(5284):99-102
82. Hsiao KK, Groth D, Scott M, Serban H, Rapp D, et al. 1994. Serial transmission in rodents of neurodegeneration from transgenic mice expressing mutant prion protein. Proc. Natl. Acad. Sci. USA 91:9126-30
83. Hutton M, Lewis J, Dickson D, Yen SH, McGowan E. 2001. Analysis of tauopathies with transgenic mice. Trends Mol. Med. 7:467-70
84. Jackson GS, Hosszu LL, Power A, Hill AF, Kenney J, et al. 1999. Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. Science 283(5409):1935-37
85. Jarrett JT, Berger EP, Lansbury PT Jr. 1993. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32:4693-97
86. Jarrett JT, Lansbury PT Jr. 1993. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73:1055-58
87. Jeffrey M, Halliday WG, Bell J, Johnston AR, MacLeod NK, et al. 2000. Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infected murine hippocampus. Neuropathol. Appl. Neurobiol. 26(1):41-54
88. RES in murine ME7 scrapie in relation to pathological and PrP immunohistochemical changes. J. Comp. Pathol. 124:20-28
89. Jensen PH, Nielsen MS, Jakes R, Dotti CG, Goedert M. 1998. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 273:26,292-94
90. Johnston JA, Dalton MJ, Gurney ME, Kopito RR. 2000. Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 97:12,571-76
91. Johnston JA, Ward CL, Kopito RR. 1998. Aggresomes: a cellular response to misfolded proteins. J. Cell. Biol. 143:1883-98
92. Julien JP. 2001. Amyotrophic lateral sclerosis: unfolding the toxicity of the misfolded. Cell 104:581-91
93. Kagan BL, Hirakura Y, Azimov R, Azimova R. 2001. The channel hypothesis of Huntington's disease. Brain Res. Bull. 56(3):281-84
94. Kagan BL, Hirakura Y, Azimov R, Azimova R, Lin MC. 2002. The channel hypothesis of Alzheimer's disease: current status. Peptides 23(7):1311-15
95. Kaneko K, Ball HL, Wille H, Zhang H, Groth D, et al. 2000. A synthetic peptide initiates Gerstmann-Straussler-Scheinker (GSS) disease in transgenic mice. J. Mol. Biol. 295:997-1007
96. Kato S, Takikawa M, Nakashima K, Hirano A, Cleveland DW, et al. 2000. New consensus research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: inclusions containing SOD1 in neurons and astrocytes. 1:163-84
97. Kirkitadze MD, Condron MM, Teplow DB. 2001. Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis. J. Mol. Biol. 312(5):1103-19
98. Knaus KJ, Morillas M, Swietnicki W, Malone M, Surewicz WK, Yee VC. 2001. Crystal structure of the human prion protein reveals a mechanism for oligomerization. Nat. Struct. Biol. 8(9):770-74
99. Kocisko DA, Come JH, Priola SA, Chesebro B, Raymond GJ, et al. 1994. Cell-free formation of protease-resistant prion protein. Nature 370:471-74
100. Koistinaho M, Ort M, Cimadevilla JM, Vondrous R, Cordell B, et al. 2001. Specific spatial learning deficits become severe with age in beta-amyloid precursor protein transgenic mice that harbor diffuse beta-amyloid deposits but do not form plaques. Proc. Natl. Acad. Sci. USA 98:14,675-80
101. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, et al. 1998. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95:6448-53
102. Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, et al. 2001. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 79:595-605
103. Lansbury PT, Brice A. 2002. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr. Opin. Genet. Dev. 12:299-306
104. Lansbury PT Jr. 1999. Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc. Natl. Acad. Sci. USA 96:3342-44
105. Lashuel H, Petre B, Wall J, Simon M, Nowak R, et al. 2002a. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322:1089-102
106. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr. 2002b. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418:291
107. Lasmezas CI, Deslys JP, Robain O, Jaegly A, Beringue V, et al. 1997. Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 275(5298):402-5
108. Lee HJ, Lee SJ. 2002. Characterization of cytoplasmic alpha-synuclein aggregates: fibril formation is tightly linked to the inclusion forming process in cells. J. Biol. Chem. 277:48,976-83
109. Lee MK, Stirling W, Xu Y, Xu X, Qui D, et al. 2002. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA 99:8968-73
110. Lee SJ, Liyanage U, Bickel PE, Xia W, Lansbury PT Jr, Kosik KS. 1998. A detergent-insoluble membrane compartment contains A beta in vivo. Nat. Med. 4:730-34
111. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. 1996. Sequence of deposition of heterogeneous amyloid beta-peptides and APOE in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3:16-32
112. Li J, Uversky VN, Fink AL. 2001. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40:11,604-13
113. Liemann S, Glockshuber R. 1999. Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein. Biochemistry 38(11):3258-67
114. Lin H, Bhatia R, Lal R. 2001. Amyloid β-protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J. 15:2433-44
115. Lin MC, Mirzabekov T, Kagan BL. 1997. Channel formation by a neurotoxic prion protein fragment. J. Biol. Chem. 272(1):44-47
116. Liu Y, Fallon L, Lashuel HA, Liu Z. 2002. Atypical ubiquity 1 ligase activity of UCH-L1 may explain its link to Parkinson's disease susceptibility. Cell 111:209-18
117. LoBianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. 2002. Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 99:10,813-18
118. Lorenzo A, Yankner BA. 1994. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Nat. Acad. Sci. USA 91 (25): 12,243-47
119. Lotharius J, Brundin P. 2002. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum. Mol. Genet. 11(20):2395-407
120. Ma J, Lindquist S. 2002. Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science 298:1785-88
121. Ma J, Lindquist S, Wollman R. 2002. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 298:1781-85
122. Marek K, Seibyl J, Shoulson I, Holloway R, Kieburtz K, et al. 2002. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287:1653-61
123. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, et al. 2000. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287:1265-69
124. Matsumoto S, Kusaka H, Ito H, Shibata N, Asayama T, Imai T. 1996. Sporadic amyotrophic lateral sclerosis with dementia and Cu/Zn superoxide dismutase-positive Lewy body-like inclusions. Clin. Neuropathol. 15:41-46
125. Mattiazzi M, D'Aurelio M, Gajewski CD, Martushova K, Kiaei M, et al. 2002. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J. Biol. Chem. 277:29,626-33
126. Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, et al. 1999. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann. Neurol. 46:412-16
127. McKinley MP, Meyer RK, Kenaga L, Rahbar F, Cotter R, et al. 1991. Scrapie prion rod formation in vitro requires both detergent extraction and limited proteolysis. J. Virol. 65:1340-51
128. Mehlhorn I, Groth D, Stockel J, Moffat B, Reilly D, et al. 1996. High-level expression and characterization of a purified 142-residue polypeptide of the prion protein. Biochemistry 35(17):5528-37
129. Merz PA, Somerville RA, Wisniewski HM, Iqbal K. 1981. Abnormal fibrils from scrapie-infected brain. Acta Neuropathol. 54:63-74
130. Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, et al. 1999. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274:6483-92
131. Morillas M, Vanik DL, Surewicz WK. 2001. On the mechanism of alpha-helix to beta-sheet transition in the recombinant prion protein. Biochemistry 40(23):6982-87
132. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, et al. 2000. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20:4050-58
133. Muller WEG, Ushijima H, Schroder HC, Forrest JMS, Schatton WFH, et al. 1993. Cytoprotective effect of NMDA receptor antagonists on prion protein (Prion-Sc)-induced toxicity in rat cortical cell cultures. Eur. J. Pharm. 246:261-67
134. Nandi PK, Leclerc E. 1999. Polymerization of murine recombinant prion protein in nucleic acid solution. Arch. Virol. 144(9):1751-63
135. Nahri L, Wood SJ, Steavenson S, Jiang Y, Wu GM, et al. 1999. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274:9843-46
136. Nichols MR, Moss MA, Reed DK, Lin WL, Mukhopadhyay R, et al. 2002. Growth of beta-amyloid(1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy. Biochemistry 41:6115-27
137. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, et al. 2001. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat. Neurosci. 4:887-93
138. Oesch B, Westaway D, Walchli M, McKinley MP, Kent SBH, et al. 1985. A cellular gene encodes scrapie PrP 27-30 protein. Cell 40:735-46
139. Pardo CA, Xu Z, Borchelt DR, Price DL, Sisodia SS, Cleveland DW. 1995. Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc. Natl. Acad. Sci. USA 92:954-58
140. Perutz MF, Windle AH. 2001. Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats. Nature 412:143-44
141. Petersen RB, Parchi P, Richardson SL, Urig CB, Gambetti P. 1996. Effect of the D178N mutation and the codon 129 polymorphism on the metabolism of the prion protein. J. Biol. Chem. 271:12661-68
142. Poirier MA, Li H, Macosko J, Cai S, Amzel M, Ross CA. 2002. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J. Biol. Chem. 277:41,032-37
143. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-47
144. Post K, Brown DR, Groschup M, Kretzschmar HA, Riesner D. 2000. Neurotoxicity but not infectivity of prion proteins can be induced reversibly in vitro. Arch. Virol. Suppl. (16):265-73
145. Prusiner SB, McKinley MP, Bowman KA, Bendheim PE, Bolton DC, et al. 1983. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 35:349-58
146. Qin K, Yang DS, Yang Y, Chishti MA, Meng LJ, et al. 2000. Copper(II)-induced conformational changes and protease resistance in recombinant and cellular PrP. Effect of protein age and deamidation. J. Biol. Chem. 275(25):19,121-31
147. Quaglio E, Chiesa R, Harris DA. 2001. Copper converts the cellular prion protein into a protease-resistant species that is distinct from the scrapie isoform. J. Biol. Chem. 276(14):11,432-38
148. Rakhit R, Cunningham P, Furtos-Matei A, Dahan S, Qi XF, et al. 2002. Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J. Biol. Chem. 277:47,551-56
149. Requena JR, Groth D, Legname G, Stadtman ER, Prusiner SB, et al. 2001. Copper-catalyzed oxidation of the recombinant SHa(29-231) prion protein. Proc. Natl. Acad. Sci. USA 98(13):7170-75
150. Riesner D, Kellings K, Post K, Wille H, Serban H, et al. 1996. Disruption of prion rods generates 10-nm spherical particles having high alpha-helical content and lacking scrapie infectivity. J. Virol. 70:1714-22
151. Robberecht W, Aguirre T, Van den Bosch L, Tilkin P, Cassiman JJ, Matthijs G. 1996. D90A heterozygosity in the SOD1 gene is associated with familial and apparently sporadic amyotrophic lateral sclerosis. Neurology 47:1336-39
152. Rochet J-C, Conway KA, Lansbury PT. 2000. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry 39(35):10,619-26
153. Rochet J-C, Lansbury PL. 2001. Kinetic stabilization of the α-synuclein protofribil by a dopamine-α-synuclein adduct. Science 294:1346-49
154. Rodriguez JA, Valentine JS, Eggers DK, Roe JA, Tiwari A, et al. 2002. Familial amyotrophic lateral sclerosis-associated mutations decrease the thermal stability of distinctly metallated species of human copper/zinc superoxide dismutase. J. Biol. Chem. 277:15,932-37
155. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, et al. 1993. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59-62
156. Ross C. 2002. Polyglutamine pathogenesis. Emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 35:819-22
157. Rouleau GA, Clark AW, Rooke K, Pramatarova A, Krizus A, et al. 1996. SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis. Ann. Neurol. 39:128-31
158. Saborio GP, Permanne B, Soto C. 2001. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411(6839):810-13
159. Saborio GP, Soto C, Kascsak RJ, Levy E, Kascsak R, et al. 1999. Cell-lysate conversion of prion protein into its protease-resistant isoform suggests the participation of a cellular chaperone. Biochem. Biophys. Res. Commun. 258(2):470-75
160. Safar J, Wang W, Padgett MP, Ceroni M, Piccardo P, et al. 1990. Molecular mass, biochemical composition, and physicochemical behavior of the infectious form of the scrapie precursor protein monomer. Proc. Natl. Acad. Sci. USA 87:6373-77
161. Sanghera N, Pinheiro TJ. 2002. Binding of prion protein to lipid membranes and implications for prion conversion. J. Mol. Biol. 315(5):1241-56
162. Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, et al. 1997. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90:549-58
163. Shibata N, Hirano A, Kobayashi M, Sasaki S, Kato T, et al. 1994. Cu/Zn superoxide dismutase-like immunoreactivity in Lewy body-like inclusions of sporadic amyotrophic lateral sclerosis. Neurosci. Lett. 179:149-52
164. Shibata N, Hirano A, Kobayashi M, Siddique T, Deng HX, et al. 1996. Intense superoxide dismutase-1 immunoreactivity in intracytoplasmic hyaline inclusions of familial amyotrophic lateral sclerosis with posterior column involvement. J. Neuropathol. Exp. Neurol. 55:481-90
165. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, et al. 2001. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293:263-69
166. Shinder GA, Lacourse MC, Minotti S, Durham HD. 2001. Mutant Cu/Zn-superoxide dismutase proteins have altered solubility and interact with heat shock/stress proteins in models of amyotrophic lateral sclerosis. J. Biol. Chem. 276:12,791-96
167. Singh N, Zanusso G, Chen SG, Fujioka H, Richardson S, et al. 1997. Prion protein aggregation reverted by low temperature in transfected cells carrying a prion protein gene mutation. J. Biol. Chem. 272(45):28,461-70
168. Small DH, Mok SS, Bornstein JC. 2001. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat. Rev. Neurosci. 2:595-98
169. Soto C, Kascsak RJ, Saborio GP, Aucouturier P, Wisniewski T, et al. 2000. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet 355(9199):192-97
170. Spillantini MG, Schmidt JL, Lee VM, Trojanowski JQ, Jakes R, et al. 1997. Alpha-synuclein in Lewy bodies. Nature 388 (6645):839-40
171. Steiner H, Revesz T, Neumann M, Romig H, Grim MG, et al. 2001. A pathogenic presenilin-1 deletion causes abberrant Abeta 42 production in the absence of congophilic amyloid plaques. J. Biol. Chem. 276:7233-39
172. Stewart RS, Harris DA. 2001. Most pathogenic mutations do not alter the membrane topology of the prion protein. J. Biol. Chem. 276(3):2212-20
173. Stieber A, Gonatas JO, Collard J, Meier J, Julien J, et al. 2000. The neuronal Golgi apparatus is fragmented in transgenic mice expressing a mutant human SOD1, but not in mice expressing the human NF-H gene. J. Neurol. Sci. 173:63-72
174. Tagliavini F, Forloni G, D'ursi P, Bugiani M, Salmona M. 2001. Studies on peptide fragments of prion protein. Adv. Prot. Chem. 57:171-202
175. Taylor JP, Hardy J, Fischbeck KH. 2002. Toxic proteins in neurodegenerative disease. Science 296:1991-95
176. Turk E, Teplow DB, Hood LE, Prusiner SB. 1988. Purification and properties of the cellular and scrapie hamster prion proteins. Eur. J. Biochem. 176:21-30
177. Urbanc B, Cruz L, Le R, Sanders J, Ashe KH, et al. 2002. Neurotoxic effects of thioflavin S-positive amyoid deposits in transgenic mice and Alzeheimer's disease. Proc. Natl. Acad. Sci. USA 99:13,990-95
178. Uversky VN, Li J, Souillac P, Millett IS, Doniach S, et al. 2002. Biophysical properties of the synucleins and their propensities to fibrilate. Inhibition of alpha-synuclein assembly by beta and gamma synucleins. J. Biol. Chem. 277(14):11,970-78
179. Volles MJ, Lansbury PT Jr. 2002. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41:4595-602
180. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, et al. 2001. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40:7812-19
181. Vorberg I, Priola SA. 2002. Molecular basis of scrapie strain glycoform variation. J. Biol. Chem. 277(39):36,775-81
182. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, et al. 1999. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274:25,945-52
183. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, et al. 2002. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-39
184. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. 1997. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272:22,364-72
185. Wang J, Xu GL, Gonzales V, Cornfield M, Fromholt D, et al. 2002. Fibrillar inclusions and motor neuron degeneration in transgenci mice expressing superoxide dismutase 1 with a disrupted copper-binding site. Neurobiol. Dis. 10:128-38
186. Welker E, Raymond LD, Scheraga HA, Caughey B. 2002. Intramolecular versus intermolecular disulfide bonds in prion proteins. J. Biol. Chem. 277:33,477-81
187. Welker E, Wedemeyer WJ, Scheraga HA, 2001. A role for intermolecular disulfide bonds in prion diseases? Proc. Natl. Acad. Sci. USA 98(8):4334-36
188. Westaway D, DeArmond SJ, Cayetano-Canlas J, Groth D, Foster D, et al. 1994. Degeneration of skeletal muscle, peripheral nerves, and the central nervous system in transgenic mice overexpressing wild-type prion proteins. Cell 76:117-29
189. Wille H, Michelitsch MD, Guenebaut V, Supattapone S, Serban A, et al. 2002. Structural studies of the scrapie prion protein by electron crystallography. Proc. Natl. Acad. Sci. USA 99(6):3563-68
190. Wilson CA, Doms RW, Zheng H, Lee VM. 2002. Presenilins are not required for A beta 42 production in the early secretory pathway. Nat. Neurosci. 5:849-55
191. Wong PC, Cai H, Borchelt DR, Price DL. 2002. Genetically engineered mouse models of neurodegenerative diseases. Nat. Neurosci. 5:633-39
192. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL. 1999. Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274:19,509-12
193. Wuthrich K, Riek R. 2001. Three-dimensional structures of prion proteins. Adv. Prot. Chem. 57:55-82
194. Xiong LW, Raymond LD, Hayes SF, Raymond GJ, Caughey B. 2001. Conformational change, aggregation and fibril formation induced by detergent treatments of cellular prion protein. J. Neurochem. 79(3):669-78
195. Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA. 2002. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8:600-6
196. Yankner BA, Duffy LK, Kirschner DA. 1990. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250:279-82
197. Zhang H, Stockel J, Mehlhorn I, Groth D, Baldwin MA, et al. 1997. Physical studies of conformational plasticity in a recombinant prion protein. Biochemistry 36:3543-53
198. Zhang Y, McLaughlin R, Goodyer C, LeBlanc A. 2002. Selective cytotoxicity of intracellular amyloid beta peptide 1-42 through p53 and Bax in cultured primary human neurons. J. Cell Biol. 156:519-29
199. Zhou W, Schaack J, Zawada WM, Freed CR. 2002. Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res. 926:42-50